"...the complex world of China’s hybrid economic system that blurs private and public, civilian and military to meet the goals of the State. This system creates market distortions and undermines the global norms of science by leveraging researchers as well as academic and commercial entities to further national priorities, rather than open, mutually beneficial collaborations or fair commercial competition that fosters innovation and is free from market-distorting subsidies and restrictions. Through its policies and programs, China uses the power of the State to not only advantage its own companies but to disadvantage others, with the goal of dominating these industries of the future. "Despite the importance of genomics and initial investments into the Human Genome Project, the U.S. still lacks a comprehensive national strategy for the bioeconomy. China will gain an advantage in technology competition if we don’t acknowledge and address those areas where national security and market forces diverge. The early stages of development for these new knowledge-based industries—such as biotechnology—will be most critical for government support and policies."
??New Biotech Report?? China’s industrial policies are skewing the biotech playing field. In their new report, Anna Puglisi & Chryssa Rask explore how Beijing is using the playbook that worked for Huawei and 5G to build up BGI. Read the full report: https://lnkd.in/eFUqfdYR
